Targeting various COVID variants by altering spike protein structure

Versatile antiviral nanoparticles, effective across SARS-CoV-2 variants.

First SARS-CoV-2 vaccinations immune response to new virus variants

Immunological imprinting impacts human antibody reaction to SARS-CoV-2 mutations.

MIT researchers are using new nanoparticles to improve vaccines

Zeolitic imidazolate frameworks boost SARS-CoV-2 spike protein trimer immunity via Toll-like receptor activation.

Iron deficiency from infection may trigger long COVID

Iron imbalance and inflammatory stress affect COVID-19 outcomes.

Current antiviral treatment course is inadequate for high-risk COVID-19

Molnupiravir's impact on SARS-CoV-2 response in at-risk outpatients.

SARS-CoV-2 variants: How a set of key covariates affect viral kinetics?

A prospective observational cohort study.

Breakthrough RNA mapping method by HIRI researchers

SHIFTR allows unbiased protein identification on RNA regions in live cells.

The complement system damages cells in long-term COVID

Persistent complement dysfunction in long COVID: Inflammation and blood clot risks.

Influenza immunity spurs rapid protection in new vaccine

Influenza boosts antibody power against SARS-CoV-2.

How ultraviolet light degrades coronavirus?

SARS-CoV-2 has among the largest of genomes for RNA viruses.

COVID-19 changes gene activity in olfactory mucosal cells in Alzheimer’s

Distinct immune responses after infection between AD patients and healthy individuals.

SARS-CoV-2 moves within neurons to infect the brain

Separate effects: SARS-CoV-2, neuroinvasion, and anosmia.

Recent Stories